Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v34-EN Version v19-FR
Language English French
Date Updated 2021-09-02 2020-03-05
Drug Identification Number 02316412 02316412
Brand name TEVA-IRBESARTAN TEVA-IRBESARTAN
Common or Proper name IRBESARTAN IRBESARTAN
Company Name TEVA CANADA LIMITED TEVA CANADA LIMITED
Ingredients IRBESARTAN IRBESARTAN
Strength(s) 300MG 300MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL
Packaging size 100 100
ATC code C09CA C09CA
ATC description ANGIOTENSIN II ANTAGONISTS, PLAIN ANGIOTENSIN II ANTAGONISTS, PLAIN
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2019-07-02 2019-07-02
Estimated end date 2021-09-30 2020-04-30
Actual end date
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments Will continue to allocate until regular supply can be restored (TBA)
Health Canada comments